ARA-290
ARA-290, also called cibinetide, is a peptide derived from a region of erythropoietin. It was designed to engage tissue-protective signalling without stimulating red blood cell production.
Early clinical studies have examined small-fibre neuropathy and diabetes-related nerve symptoms. Research in this area continues to grow, and any protocol begins with physician assessment.
What Is ARA-290?
ARA-290 is a synthetic peptide developed to separate proposed tissue-protective effects from erythropoietin's blood-forming effects.
It is distinct from erythropoietin medicines, with its own research profile and physician-guided applications.
How Does ARA-290 Work?
ARA-290 is described as an agonist of the innate repair receptor, a proposed receptor complex involving erythropoietin-receptor and beta-common-receptor components.
Activation of this pathway has been studied for effects on inflammatory signalling and tissue protection, and clinical research continues to explore nerve-related applications.
What Has Research Studied?
Small clinical studies have examined neuropathic symptoms in sarcoidosis and type 2 diabetes. Assessments have included symptom questionnaires and measures related to small nerve fibres.
Early signals are being explored in larger, well-controlled studies with longer follow-up.
Safety and Medical Supervision
Longer studies continue to build the evidence base, and treatment at MRC includes physician monitoring throughout.
A physician should investigate the cause of nerve symptoms and optimise established care. Diabetes management, foot assessment and appropriate pain treatment should continue.
Frequently Asked Questions
Can ARA-290 reverse diabetic nerve damage?
Early studies have assessed symptoms and nerve-related measures, and research into durable nerve repair continues.
Is ARA-290 the same as erythropoietin?
It is a distinct peptide designed to engage a proposed tissue-protective pathway without erythropoietin's red-cell-stimulating action.
Has ARA-290 been studied in people?
Yes. Early trials have included people with sarcoidosis-associated neuropathy and type 2 diabetes, but the evidence remains limited.
What should I do about new numbness or burning pain?
Arrange medical assessment. Several conditions can cause these symptoms, and weakness, foot wounds or rapidly worsening symptoms need prompt attention.
References
- PubMed. ARA 290 for treatment of small fiber neuropathy in sarcoidosis
- PubMed. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Disclaimer
This information, including but not limited to texts, images, graphics, labels, ingredients, indications, potential benefits, and other materials contained on this website are for informational purposes only. No part of this website is intended to be a substitute for professional medical advice, treatment, or diagnosis. Always seek the advice of your physician or other professional healthcare provider, particularly before starting a new regimen for the first time.
Wondering Whether ARA-290 Is Right for You?
Speak with our medical team about your health goals. We will help you understand which options are supported by evidence and appropriate for your situation.